{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:38:26Z","timestamp":1790469506175,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.revmed.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T17:55:23Z","timestamp":1604253323000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Les purpuras thrombop\u00e9niques immunologiques secondaires de l\u2019adulte"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.revmed.2020.08.004_bib0425","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.revmed.2020.08.004_bib0430","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.revmed.2020.08.004_bib0435","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.revmed.2020.08.004_bib0440","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2014-05-578336","article-title":"Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France","volume":"124","author":"Moulis","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2020.08.004_bib0445","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.24702","article-title":"Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort","volume":"92","author":"Moulis","year":"2017","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.revmed.2020.08.004_bib0450","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60\u00a0patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0455","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1054\/blre.2001.0188","article-title":"HIV-related thrombocytopenia","volume":"16","author":"Scaradavou","year":"2002","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.revmed.2020.08.004_bib0460","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jgh.12942","article-title":"Non-cirrhotic thrombocytopenic patients with hepatitis C virus: characteristics and outcome of antiviral therapy","volume":"30","author":"Giannini","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.revmed.2020.08.004_bib0465","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MD.0b013e31822618b3","article-title":"Association of sarcoidosis and immune thrombocytopenia: presentation and outcome in a series of 20\u00a0patients","volume":"90","author":"Mah\u00e9vas","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.revmed.2020.08.004_bib0470","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/ejh.12393","article-title":"Immune thrombocytopenia in chronic myelomonocytic leukemia","volume":"93","author":"Hadjadj","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0475","series-title":"Purpura thrombop\u00e9nique immunologique de l\u2019enfant et de l\u2019adulte","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2017"},{"issue":"23","key":"10.1016\/j.revmed.2020.08.004_bib0480","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019\u00a0guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.revmed.2020.08.004_bib0485","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0490","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archinte.162.9.1033","article-title":"Autoimmune thrombocytopenic purpura and Helicobacter pylori infection","volume":"162","author":"Michel","year":"2002","journal-title":"Arch Int Med"},{"issue":"8","key":"10.1016\/j.revmed.2020.08.004_bib0495","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190903026492","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic lymphoma: changes in clinical presentation and prognosis","volume":"50","author":"Zent","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.revmed.2020.08.004_bib0500","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminoncol.2006.01.011","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin","year":"2006","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.revmed.2020.08.004_bib0505","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ajh.23268","article-title":"Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia","volume":"87","author":"Reda","year":"2012","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10369","article-title":"Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"74","author":"Kyasa","year":"2003","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0515","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood-2007-09-111492","article-title":"Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia","volume":"111","author":"Visco","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.revmed.2020.08.004_bib0520","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1600-0609.2010.01527.x","article-title":"Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21\u00a0patients","volume":"85","author":"D\u2019Arena","year":"2010","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0525","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2010.278","article-title":"Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia","volume":"25","author":"Rossignol","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.revmed.2020.08.004_bib0530","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/10428191003682767","article-title":"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia\/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone","volume":"51","author":"Bowen","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.revmed.2020.08.004_bib0535","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.14788","article-title":"Use of eltrombopag for secondary immune thrombocytopenia in clinical practice","volume":"178","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.revmed.2020.08.004_bib0540","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1182\/blood.2019001617","article-title":"Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2\u00a0multicenter study","volume":"134","author":"Visco","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0545","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.15545","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre","volume":"183","author":"Hampel","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0550","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/10428199909050962","article-title":"Autoimmunity in Waldenstr\u00f6m's macroglobulinaemia","volume":"34","author":"J\u00f8nsson","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.revmed.2020.08.004_bib0555","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJM198701223160406","article-title":"Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease","volume":"316","author":"Lehman","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.revmed.2020.08.004_bib0560","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.revmed.2020.08.004_bib0565","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2020.08.004_bib0570","first-page":"235","article-title":"Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637\u00a0cases and comparison with myeloproliferative diseases","volume":"67","author":"D\u00fchrsen","year":"1987","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0575","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.bmt.1704073","article-title":"Autoimmune thrombocytopenic purpura after autologous stem cell transplantation","volume":"32","author":"Hequet","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0580","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3324\/haematol.11934","article-title":"Autoimmune thrombocytopenia in non-Hodgkin's lymphomas","volume":"93","author":"Hauswirth","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.revmed.2020.08.004_bib0585","first-page":"669","article-title":"Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin's disease in complete hematological remission","volume":"83","author":"Martinelli","year":"1998","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0590","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9343(01)00775-6","article-title":"Immune thrombocytopenic purpura: first symptom of gamma\/delta T -cell lymphoma","volume":"111","author":"Garderet","year":"2001","journal-title":"Am J Med"},{"issue":"3\u20134","key":"10.1016\/j.revmed.2020.08.004_bib0595","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10428199509059623","article-title":"Autoimmune phenomena in non-Hodgkin's lymphoma","volume":"18","author":"Gr\u00f8nbaek","year":"1995","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0600","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/ejh.13239","article-title":"Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma","volume":"103","author":"Crickx","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0605","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000\u00a0patients","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0610","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/39.4.399","article-title":"A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population","volume":"39","author":"Mok","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0615","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/keh048","article-title":"Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations","volume":"43","author":"Vil\u00e1","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0620","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/ard.2004.033100","article-title":"Lupus thrombocytopenia: clinical implications and prognostic significance","volume":"64","author":"Ziakas","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2020.08.004_bib0625","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/0961203312438630","article-title":"Clinical implications and prognostic significance of thrombocytopenia in Tunisian patients with systemic lupus erythematosus","volume":"21","author":"Jallouli","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2020.08.004_bib0630","doi-asserted-by":"crossref","first-page":"e2818","DOI":"10.1097\/MD.0000000000002818","article-title":"Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230\u00a0patients","volume":"95","author":"Jung","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0635","doi-asserted-by":"crossref","first-page":"102395","DOI":"10.1016\/j.autrev.2019.102395","article-title":"Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"18","author":"Chock","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2020.08.004_bib0640","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.2002.03817.x","article-title":"Platelet autoantibodies and lupus-associated thrombocytopenia","volume":"119","author":"Michel","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0645","first-page":"806","article-title":"Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE)","volume":"8","author":"Cela","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0650","article-title":"Successful use of azathioprine in glucocorticoid refractory immune amegakaryocytic thrombocytopenia of lupus","author":"Gupta","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.revmed.2020.08.004_bib0655","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V67.2.479.479","article-title":"Cell-mediated amegakaryocytic thrombocytopenia associated with systemic lupus erythematosus","volume":"67","author":"Nagasawa","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.004_bib0660","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/art.10420","article-title":"Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia","volume":"46","author":"Kuwana","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.08.004_bib0665","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1191\/0961203302lu177oa","article-title":"Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus","volume":"11","author":"F\u00fcreder","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2020.08.004_bib0670","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2016.07.001","article-title":"The diagnosis and management of the haematologic manifestations of lupus","volume":"74","author":"Velo-Garc\u00eda","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2020.08.004_bib0675","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/art.1780330105","article-title":"Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death","volume":"33","author":"Reveille","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.08.004_bib0680","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjms.2019.03.002","article-title":"Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis","volume":"357","author":"Chen","year":"2019","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.revmed.2020.08.004_bib0685","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/rheumatology\/kem180","article-title":"Causes and predictors of death in South Africans with systemic lupus erythematosus","volume":"46","author":"Wadee","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0690","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.1996.00440110109015","article-title":"Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus","volume":"156","author":"Ward","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2020.08.004_bib0695","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59\u00a0cases","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0700","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/acr.22591","article-title":"Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines","volume":"67","author":"Tunnicliffe","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0705","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/acr.22589","article-title":"Treatment algorithms in systemic lupus erythematosus","volume":"67","author":"Muangchan","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0710","doi-asserted-by":"crossref","first-page":"e7534","DOI":"10.1097\/MD.0000000000007534","article-title":"Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: a PRISMA-compliant systematic review and meta-analysis of 28\u00a0studies","volume":"96","author":"Weber","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.revmed.2020.08.004_bib0715","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and Safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21\u00a0cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0720","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.revmed.2020.08.004_bib0725","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71\u00a0adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.revmed.2020.08.004_bib0730","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248\u00a0adults with immune thrombocytopenia: results at 5\u00a0years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0735","article-title":"Eltrombopag: efficacy and safety in steroid refractory lupus-associated immune thrombocytopenia","author":"Shobha","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0740","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0961203314559632","article-title":"Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus","volume":"24","author":"Maroun","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2020.08.004_bib0745","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.revmed.2020.08.004_bib0750","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0755","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-102-3-325","article-title":"Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus","volume":"102","author":"Hall","year":"1985","journal-title":"Ann Intern Med"},{"issue":"48","key":"10.1016\/j.revmed.2020.08.004_bib0760","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2020.08.004_bib0765","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/asheducation-2009.1.139","article-title":"Primary immunodeficiencies (PIDs) presenting with cytopenias","author":"Notarangelo","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0770","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248\u00a0patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0775","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.md.0000133624.65946.40","article-title":"Autoimmune Thrombocytopenic Purpura and common variable immunodeficiency: analysis of 21\u00a0cases and review of literature","volume":"83","author":"Michel","year":"2004","journal-title":"Medicine"},{"issue":"15","key":"10.1016\/j.revmed.2020.08.004_bib0780","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68\u00a0cases","volume":"114","author":"Michel","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.revmed.2020.08.004_bib0785","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33\u00a0patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0790","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.autrev.2014.08.036","article-title":"Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3\u00a0cases and systematic review of the literature","volume":"13","author":"Levy","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.revmed.2020.08.004_bib0795","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10875-016-0282-5","article-title":"Use of thrombopoietin-receptor agonist in CVID-associated immune thrombocytopenia","volume":"36","author":"Carrabba","year":"2016","journal-title":"J Clin Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0800","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cei.12039","article-title":"Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45\u00a0patients","volume":"172","author":"Wong","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0805","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2141.2009.07714.x","article-title":"Cytomegalovirus can make immune thrombocytopenic purpura refractory","volume":"146","author":"DiMaggio","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0810","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MEG.0b013e3283249908","article-title":"Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16\u00a0cases","volume":"21","author":"Dufour","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.revmed.2020.08.004_bib0815","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3748\/wjg.v20.i3.714","article-title":"Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms","volume":"20","author":"Kuwana","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"13","key":"10.1016\/j.revmed.2020.08.004_bib0820","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","article-title":"Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations","volume":"123","author":"Price","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.revmed.2020.08.004_bib0825","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V94.2.509","article-title":"The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation","volume":"94","author":"Haddad","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0830","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1\u00a0or anti-PD-L1\u00a0immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.revmed.2020.08.004_bib0835","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/ajh.25645","article-title":"Methylprednisolone-induced immune thrombocytopenia","volume":"95","author":"Dubert","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.08.004_bib0840","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17024","article-title":"Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series","author":"Mah\u00e9vas","year":"2020","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.revmed.2020.08.004_bib0900","first-page":"S12","article-title":"Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood","volume":"60","author":"Price","year":"2013","journal-title":"Pediatr Blood Cancer"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:43:37Z","timestamp":1759337017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320303477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0248866320303477"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.004","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les purpuras thrombop\u00e9niques immunologiques secondaires de l\u2019adulte","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}